Evotec SE (EVO) EBITDA Margin (2009 - 2025)

Evotec SE (EVO) posted EBITDA Margin of 22.9% for Q4 2025, up 184.33% sequentially from 27.15% in Q3 2025, and up 1001.0% YoY from 2.08% in Q4 2024.

Evotec SE (EVO) EBITDA Margin (2009 - 2025) Analysis & Trends

Evotec SE has reported EBITDA Margin for 9 years, with the latest figure at 22.9% in Q4 2025.

Quarterly EBITDA Margin rose 1001.0% year-over-year to 22.9% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 1.82% (down 356.0% YoY) and the FY2025 annual result came in at 6747.84%, up 391221.0% from the prior year.
EBITDA Margin advanced to 22.9% in Q4 2025 per EVO's latest filing, from 27.15% in the prior quarter.
Over five years, EBITDA Margin peaked at 22.9% in Q4 2025 and troughed at 27.15% in Q3 2025.
A 5-year average of 4.41% and a median of 8.66% in 2023 frame the typical range for EBITDA Margin.
The sharpest annual moves came in 2024 and 2025: EBITDA Margin sank 2054 bps in 2024, then jumped 1001 bps in 2025.
Over 5 years, EBITDA Margin stood at 16.26% in 2021, then tumbled by 46 bps to 8.73% in 2022, then slipped by 1 bps to 8.66% in 2023, then surged by 49 bps to 12.88% in 2024, then surged by 78 bps to 22.9% in 2025.
According to Business Quant data, EBITDA Margin over the past three periods registered 22.9%, 27.15%, and 12.88% for Q4 2025, Q3 2025, and Q4 2024 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBITDA Margin (Qtr)
1	Haleon	44.51 Bn	43.55 Bn	-	-
2	Teva Pharmaceutical Industries	43.52 Bn	39.86 Bn	2.15 Bn	-5.58%
3	Zoetis	32.43 Bn	30.75 Bn	1.05 Bn	33.91%
4	Takeda Pharmaceutical	28.63 Bn	22.83 Bn	5.10 Bn	16.51%
5	United Therapeutics	21.87 Bn	19.21 Bn	683.80 Mn	42.23%
6	Viatris	18.98 Bn	18.09 Bn	1.46 Bn	0.17%
7	Neurocrine Biosciences	15.43 Bn	15.04 Bn	935.80 Mn	15.80%
8	Elanco Animal Health	12.02 Bn	11.49 Bn	798.00 Mn	18.13%
9	Dr Reddys Laboratories	10.14 Bn	9.98 Bn	-	-
10	Evotec SE	687.23 Mn	686.75 Mn	-	-

Download Data